Immunize patients with meningococcal vaccinations at least 2 weeks prior to treatment1
The 2021 Advisory Committee on Immunization Practices (ACIP) recommends the following meningococcal vaccination regimens for adult patients (aged ≥19 years) with persistent complement component deficiency or in patients receiving complement inhibitors, including patients receiving SOLIRIS1
Please refer to the most up-to-date ACIP recommendations for complete information on meningococcal vaccination in people with persistent complement component deficiencies and who are being treated with complement inhibitors, such as SOLIRIS.
Vaccinations are necessary before treatment with SOLIRIS2
- The use of SOLIRIS increases a patient’s susceptibility to life-threatening and fatal meningococcal infections (septicemia and/or meningitis), which have occurred in patients treated with SOLIRIS
- Comply with the most current ACIP recommendations for meningococcal vaccination in patients with complement deficiencies and patients receiving a complement inhibitor
- Immunize patients with meningococcal vaccines at least 2 weeks prior to administering the first dose of SOLIRIS, unless the risks of delaying therapy outweigh the risk of developing a meningococcal infection
- If urgent SOLIRIS therapy is indicated in an unvaccinated patient, initiate the vaccine regimen as soon as possible and provide 2 weeks of antibacterial drug prophylaxis
- Vaccination reduces, but does not eliminate, the risk of meningococcal infections
-
- Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate immediately if an infection is suspected